| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41571-018-0058-3 |
| P698 | PubMed publication ID | 29968853 |
| P50 | author | Nicolai Juul Birkbak | Q30419944 |
| P2093 | author name string | Charles Swanton | |
| Christopher Abbosh | |||
| P2860 | cites work | Base-calling of automated sequencer traces using phred. II. Error probabilities | Q27860615 |
| Reduced lung-cancer mortality with low-dose computed tomographic screening | Q28241954 | ||
| Age-related mutations associated with clonal hematopoietic expansion and malignancies | Q28387160 | ||
| Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes | Q28392451 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| The origin and evolution of mutations in acute myeloid leukemia | Q29614630 | ||
| Analysis of circulating tumor DNA to monitor metastatic breast cancer | Q29614797 | ||
| Detection and quantification of rare mutations with massively parallel sequencing | Q30472217 | ||
| Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. | Q30652903 | ||
| An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 | ||
| Detection of cancer DNA in plasma of patients with early-stage breast cancer. | Q33624889 | ||
| Overdiagnosis in low-dose computed tomography screening for lung cancer | Q33691938 | ||
| Characterization of background noise in capture-based targeted sequencing data | Q33922681 | ||
| Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer | Q33988009 | ||
| Cytosine deamination is a major cause of baseline noise in next-generation sequencing | Q34243350 | ||
| Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. | Q34278191 | ||
| Detection of ultra-rare mutations by next-generation sequencing | Q34291814 | ||
| Integrated digital error suppression for improved detection of circulating tumor DNA | Q34520008 | ||
| Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Q34533164 | ||
| Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer. | Q34635787 | ||
| Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology | Q35584856 | ||
| Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease | Q35909641 | ||
| Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study | Q36229421 | ||
| Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study. | Q36233903 | ||
| Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin | Q36468959 | ||
| Genomic landscape of non-small cell lung cancer in smokers and never-smokers | Q36851245 | ||
| Monitoring Error Rates In Illumina Sequencing | Q37262546 | ||
| Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery | Q37593245 | ||
| Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review | Q38196404 | ||
| The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing | Q38664177 | ||
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. | Q38798543 | ||
| Liquid biopsies come of age: towards implementation of circulating tumour DNA. | Q39149201 | ||
| Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery | Q40394915 | ||
| Risk Factors for Local and Distant Recurrence After Surgical Treatment in Patients With Non-Small-Cell Lung Cancer | Q40937741 | ||
| Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients | Q41524917 | ||
| Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. | Q43045850 | ||
| Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group | Q43463195 | ||
| Direct detection of early-stage cancers using circulating tumor DNA. | Q46035548 | ||
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution | Q46365334 | ||
| Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma | Q46984199 | ||
| Detection and localization of surgically resectable cancers with a multi-analyte blood test. | Q48216212 | ||
| Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. | Q48507434 | ||
| Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer | Q48655131 | ||
| Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. | Q50128100 | ||
| Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. | Q50943248 | ||
| Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. | Q51815597 | ||
| Cell-free DNA as a post-treatment surveillance strategy: current status. | Q52341333 | ||
| False positive plasma genotyping due to clonal hematopoiesis. | Q52641869 | ||
| Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. | Q52674273 | ||
| Polymerase specific error rates and profiles identified by single molecule sequencing. | Q54218104 | ||
| The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer | Q57272532 | ||
| Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography | Q70799723 | ||
| Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection | Q79674563 | ||
| Tumour microenvironment: informing on minimal residual disease in solid tumours | Q87805126 | ||
| P433 | issue | 9 | |
| P921 | main subject | non-small-cell lung carcinoma | Q3658562 |
| P304 | page(s) | 577-586 | |
| P577 | publication date | 2018-09-01 | |
| P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
| P1476 | title | Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection | |
| P478 | volume | 15 |
| Q90259957 | A framework for the development of effective anti-metastatic agents |
| Q91272659 | A view on drug resistance in cancer |
| Q92356109 | Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer |
| Q91726224 | Changes in store for early-stage non-small cell lung cancer |
| Q92026475 | Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma |
| Q99616869 | Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond |
| Q64899007 | Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). |
| Q92288059 | Detection of circulating sarcoma tumor cells using a microfluidic chip-type cell sorter |
| Q92283498 | High efficiency error suppression for accurate detection of low-frequency variants |
| Q91621196 | How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? |
| Q89622486 | Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity |
| Q58080418 | Liquid Biopsies |
| Q91845060 | Liquid biopsy and minimal residual disease - latest advances and implications for cure |
| Q95840544 | Liquid biopsy for early stage lung cancer moves ever closer |
| Q64914336 | Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study. |
| Q100569844 | Non-invasive detection of biliary tract cancer by low-coverage whole genome sequencing from plasma cell-free DNA: A prospective cohort study |
| Q94453247 | Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer |
| Q98186316 | Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors |
| Q90319606 | Personalized adjuvant treatment: go through the past to the future |
| Q90410227 | Plasma Long Non-Coding RNA RP11-438N5.3 as a Novel Biomarker for Non-Small Cell Lung Cancer |
| Q96304155 | Responses to ALK Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel HPCAL1-ALK Fusion Variant: A Case Report |
| Q90664748 | SLAM-MS: Mutation scanning of stem-loop amplicons with TaqMan probes by quantitative DNA melting analysis |
| Q91828624 | THUMPD3-AS1 Is Correlated With Non-Small Cell Lung Cancer And Regulates Self-Renewal Through miR-543 And ONECUT2 |
| Q64112101 | The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis |
| Q89525803 | The potential of combined mutation sequencing of plasma circulating cell-free DNA and matched white blood cells for treatment response prediction |
| Q90079694 | Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules |
| Q92914475 | Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells |
| Q92977873 | White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer |
| Q91965828 | [Investigation on the Possibility of EGFR Mutation Testing on DNA Extracted from Fixation Liquid of Lung Cancer Biopsy] |
| Q61810937 | miR‑505 inhibits cell growth and EMT by targeting MAP3K3 through the AKT‑NFκB pathway in NSCLC cells |
Search more.